Revelation Biosciences (Revelation Biosciences) 5-Year Yield-on-Cost % : 0.00 (As of May. 29, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences 5-Year Yield-on-Cost %?

Revelation Biosciences's yield on cost for the quarter that ended in Mar. 2024 was 0.00.

The historical rank and industry rank for Revelation Biosciences's 5-Year Yield-on-Cost % or its related term are showing as below:

REVB's 5-Year Yield-on-Cost % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.78
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Revelation Biosciences's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Revelation Biosciences's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revelation Biosciences's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's 5-Year Yield-on-Cost % falls into.

Revelation Biosciences 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Revelation Biosciences is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

Revelation Biosciences (NAS:REVB) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Revelation Biosciences 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

Revelation Biosciences (Revelation Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (NAS:REVB) » Definitions » 5-Year Yield-on-Cost %

Comparable Companies

Traded in Other Exchanges

56U1:Germany

Address

4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122

Website

https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Executives

George F Tidmarsh	director, 10 percent owner
Lakhmir S Chawla	director	1960 KIRBY ROAD, MCLEAN VA 22101
Axa Im Prime Impact Gp S.a.r.l	other: Former 10% owner	2-4, RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453
Axa Im Prime Impact Master Fund I Sca Sicav-raif	other: Former 10% Owner	2-4 RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453
Axa Investment Managers S.a.	other: Former 10% owner	6 PLACE DE LA PYRAMIDE, TOUR MAJUNGA, PUTEAUX I0 92800
Axa Investment Managers Paris	other: Former 10% owner	6 PLACE DE LA PYRAMIDE, PUTEAUX I0 92800
Axa Investment Managers Uk Ltd	other: Former 10% owner	22 BISHOPGATE, LONDON X0 EC2M 3XJ
S.a. Axa	other: Former 10% owner	25 AVENUE MATIGNON, PARIS I0 75008
Jess Roper	director	5555 OBERLIN DRIVE, SAN DIEGO CA 92121
James Rolke	director, officer: Chief Executive Officer	10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Curt H Labelle	director	C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011
Jennifer Carver	director	725 NEWPORT STREET, DENVER CO 80220
Zygmont Chester Stanley Iii	officer: Chief Financial Officer	3322 MILLIKIN AVE, SAN DIEGO CA 92122
Lawrence Feis	10 percent owner	190 EAST WALTON PLACE, UNIT 603, CHICAGO IL 60611
Feis Equities Llc	10 percent owner	20 NORTH WACKER DRIVE, SUITE 2115, CHICAGO IL 60606